Nurix Therapeutics, Inc. Stock Price, News & Analysis

Nurix Therapeutics (Nasdaq: NRIX) has initiated Phase 1b expansion cohorts of its ongoing trial for NX-2127, a BTK degrader, focusing on patients with chronic lymphocytic leukemia (CLL). This decision follows promising results from the Phase 1a study, revealing significant clinical benefits in heavily pre-treated patients. Key findings include confirmed responses in patients resistant to current therapies and robust BTK degradation. The R&D Day on May 26 will detail further data and future plans for NX-2127, which aims to address unmet needs in cancer treatment.

Nurix Therapeutics (Nasdaq: NRIX) announced the dosing of the first patient in its Phase 1a/1b trial for NX-5948, a selective degrader of Bruton’s tyrosine kinase (BTK), targeting relapsed B-cell malignancies. This open-label, dose escalation trial is ongoing across multiple UK centers, focusing on safety and tolerability. Initial data is expected in H2 2022. NX-5948 aims to address resistance seen with current BTK inhibitors. Nurix has four clinical trials running, with upcoming data catalysts anticipated over the next year.

Nurix Therapeutics, a clinical stage biopharmaceutical company (Nasdaq: NRIX), announced that CEO Arthur T. Sands will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on May 18th, 2022, at 11:00 a.m. ET. The event will be available via a live webcast and replay on the company's website. Nurix is focused on developing targeted protein modulation drugs through its DELigase platform, aimed at innovating cancer and other disease treatments.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) will host an R&D Day on May 26, 2022, from 8:00 a.m. to 11:00 a.m. ET in New York City. The event will feature Dr. Anthony Mato, Director of the CLL Program at Memorial Sloan Kettering Cancer Center, discussing unmet needs in hematologic malignancies. Nurix's management will present updates on their four clinical programs and the DELigase^® discovery platform. A live webcast will be available on their website.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) shared preclinical data at the AACR Annual Meeting, showcasing the potential of investigative therapies NX-2127 and DeTIL-0255 for treating B-cell malignancies and solid tumors. Key findings include NX-2127's unique ability to degrade Bruton’s tyrosine kinase (BTK) and IMiD neosubstrates, enhancing tumor cell killing. Additionally, NX-0255 was shown to enhance T-cell persistence and anti-tumor response in animal models. Nurix expects to provide clinical updates from both programs in H2 2022, following promising initial trial results.

Nurix Therapeutics (NRIX) reported encouraging developments, including the first patient dosed in the Phase 1 trial of DeTIL-0255, a drug-enhanced cell therapy for advanced gynecologic cancers. The company secured an Innovation Passport for NX-1607 from the UK for solid tumor treatment, facilitating faster market access. Financially, Nurix holds $385.7 million in cash and investments as of February 28, 2022, despite a net loss of $42.5 million for Q1 2022, compared to $24.3 million in Q1 2021. Collaboration revenue increased to $9.6 million, driven by milestones from Gilead and Sanofi.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced the dosing of its first patient in a Phase 1 clinical trial for DeTIL-0255, a drug-enhanced tumor infiltrating lymphocyte therapy targeting advanced gynecological cancers. This therapy combines patient-derived TILs treated with NX-0255, a CBL-B inhibitor, developed through Nurix's DELigase platform. The study aims to assess safety and efficacy in ovarian, cervical, and endometrial cancer patients. Initial results are expected in the second half of 2022, representing a significant milestone in combining targeted protein modulation with cell therapy.

Nurix Therapeutics (Nasdaq: NRIX) announced that CEO Arthur T. Sands will join a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 2:15 PM ET. The session will be broadcast live and can be accessed via Nurix's website, with an archived version available for 30 days post-event. Nurix is focused on discovering and developing drugs that modulate protein levels to treat cancer and other diseases through its innovative platform targeting E3 ligases.

Nurix Therapeutics has received the Innovation Passport designation from the UK MHRA for its drug candidate NX-1607, aimed at treating advanced solid tumors. This designation supports Nurix's regulatory strategy, facilitating faster development and access to the Innovative Licensing and Access Pathway. NX-1607, an orally bioavailable inhibitor designed to enhance T-cell activation, is currently undergoing a Phase 1 trial. Initial pharmacokinetic and pharmacodynamic data is expected in mid-2022, indicating potential advancements in treatment options for solid tumor patients.